Joseph Icenogle Selected Research

Rubella (German Measles)

3/2022	Drug Sensitivity of Vaccine-Derived Rubella Viruses and Quasispecies Evolution in Granulomatous Lesions of Two Ataxia-Telangiectasia Patients Treated with Nitazoxanide.
12/2020	Rubella virus-associated chronic inflammation in primary immunodeficiency diseases.
1/2020	Rubella virus-specific humoral immune responses and their interrelationships before and after a third dose of measles-mumps-rubella vaccine in women of childbearing age.
1/2020	WHO international standard for anti-rubella: learning from its application.
10/2019	Infectious vaccine-derived rubella viruses emerge, persist, and evolve in cutaneous granulomas of children with primary immunodeficiencies.
1/2019	Outcomes for Nitazoxanide Treatment in a Case Series of Patients with Primary Immunodeficiencies and Rubella Virus-Associated Granuloma.
11/2018	Epidemiology of rubella infection and genotyping of rubella virus in Cote d'Ivoire, 2012-2016.
11/2017	Inhibition of rubella virus replication by the broad-spectrum drug nitazoxanide in cell culture and in a patient with a primary immune deficiency.
9/2017	Rubella Surveillance and Diagnostic Testing among a Low-Prevalence Population, New York City, 2012-2013.
12/2016	Analysis of complete genomes of the rubella virus genotypes 1E and 2B which circulated in China, 2000-2013.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Joseph Icenogle Research Topics

Disease

19	Rubella (German Measles) 03/2022 - 12/2005
7	Granuloma 03/2022 - 11/2017
5	Measles 01/2020 - 12/2005
4	Infections 01/2019 - 01/2009
3	Exanthema (Rash) 10/2016 - 01/2009
3	Congenital Rubella Syndrome (Syndrome, Congenital Rubella) 09/2016 - 12/2005
2	Inflammation (Inflammations) 01/2021 - 12/2020
1	Ataxia Telangiectasia (Louis Bar Syndrome) 03/2022
1	Mumps 01/2020
1	Parasitic Diseases (Parasitic Disease) 11/2017
1	Primary Immunodeficiency Diseases 11/2017
1	Stillbirth 09/2016
1	Perinatal Death 09/2016
1	Vascular System Injuries 01/2016
1	Fever (Fevers) 12/2014

Drug/Important Bio-Agent (IBA)

11	VaccinesIBA 03/2022 - 12/2005
6	RNA (Ribonucleic Acid)IBA 03/2022 - 01/2009
6	Immunoglobulin M (IgM)IBA 11/2018 - 01/2009
5	AntigensIBA 01/2021 - 01/2016
3	nitazoxanide (NTZ)FDA Link 03/2022 - 11/2017
2	Pharmaceutical PreparationsIBA 03/2022 - 11/2017
2	Immunoglobulin G (IgG)IBA 01/2020 - 01/2020
2	Measles-Mumps-Rubella Vaccine (MMR Vaccine)IBA 01/2020 - 01/2019
2	EnzymesIBA 01/2020 - 11/2018
2	ImmunosorbentsIBA 01/2020 - 11/2018
2	AntibodiesIBA 11/2018 - 01/2009
1	Immunosuppressive Agents (Immunosuppressants)IBA 07/2021
1	SteroidsIBA 01/2021
1	Viral RNAIBA 12/2020
1	Neutralizing AntibodiesIBA 01/2020
1	Antiviral Agents (Antivirals)IBA 11/2017
1	Membrane Glycoproteins (Membrane Glycoprotein)IBA 11/2017
1	Proteins (Proteins, Gene)FDA Link 12/2016
1	Amino Acids FDA Link 12/2016
1	Intergenic DNA (Junk DNA)IBA 12/2014
1	NucleotidesIBA 12/2014

Therapy/Procedure

2	Salvage Therapy 03/2022 - 01/2019
1	Cell Transplantation 01/2021
1	Hematopoietic Stem Cell Transplantation 12/2020
1	Therapeutics 11/2017